Compare

Semaglutide vs BPC-157

Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.

Last reviewed . By the PeptIQ team.

863 users report co-tracking this pair (230% of Semaglutide trackers also track BPC-157).

Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.

Semaglutide

304 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 58% · Mixed 30% · Unfavorable overall 12%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Joint comfort
67
Recovery
108
Digestive comfort
159
Skin appearance
165
Appetite control
76

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Injection site reaction
163
Anxiety
188
Flushing
124
Headache
161
GI discomfort
75

Self-reported dose per injection

Median bucket: 100–200 mcg · Most common: 100–200 mcg

Reports span 25–600 mcg

25–50
4
50–100
14
100–200
18
200–400
9
400–600
10

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing28stacking16side effects24semaglutide12

How repeat users are trending

Among repeat reporters, 53% said they felt similar to their last entry, 44% more positive, and 18% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 27 days · Based on 67 repeat reporters

BPC-157

2443 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 67% · Mixed 18% · Unfavorable overall 15%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Skin appearance
-158
Appetite control
-32
Energy
-84
Mood
0
Focus
-102

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Headache
-62
GI discomfort
-133
Dizziness
-119
Fatigue
-5
Nausea
-103

Self-reported dose per injection

Median bucket: 0.6–1 mg · Most common: 0.6–1 mg

Reports span 0.05–5 mg

0.05–0.1 mg
4
0.1–0.2 mg
7
0.2–0.4 mg
12
0.4–0.6 mg
22
0.6–1 mg
31
1–2 mg
20
2–3 mg
11
3–5 mg
3

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing47stacking15side effects33bpc-15726

How repeat users are trending

Among repeat reporters, 62% said they felt similar to their last entry, 41% more positive, and 17% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 33 days · Based on 537 repeat reporters

Sources (22)

Published sources linked on the Semaglutide and BPC-157 wiki pages.

  1. FDA Drug Label

    WEGOVY (semaglutide) injection, for subcutaneous use - Prescribing Information

    Novo Nordisk. FDA Drug Label. 2021

    Source
    Wiki study page →
  2. FDA Drug Label

    OZEMPIC (semaglutide) injection, for subcutaneous use - Prescribing Information

    Novo Nordisk. FDA Drug Label. 2017

    Source
    Wiki study page →
  3. PubMed

    Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)

    Wilding JPH, Batterham RL, Calanna S, et al. N Engl J Med. 2021

    Source
    Wiki study page →
  4. ClinicalTrials.gov

    Semaglutide obesity studies on ClinicalTrials.gov

    ClinicalTrials.gov. Clinical trial registry. 2024

    Source
    Wiki study page →
  5. PubMed

    Once-Weekly Semaglutide in Adolescents with Obesity.

    Weghuber D, Barrett T, Barrientos-Pérez M, et al. N Engl J Med. 2022

    Source
    Wiki study page →
  6. PubMed

    Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.

    Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. N Engl J Med. 2023

    Source
    Wiki study page →
  7. PubMed

    Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss.

    Wharton S, Calanna S, Davies M, et al. Diabetes Obes Metab. 2022

    Source
    Wiki study page →
  8. PubMed

    Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes

    Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. The New England journal of medicine. 2023

    Source
    Wiki study page →
  9. PubMed

    GLP-1 receptor agonist discontinuation and cardiovascular events and all-cause mortality in people with type 2 diabetes: a retrospective cohort study

    Ceriello A, Prattichizzo F, Lucisano G, et al. Lancet Reg Health Eur. 2026

    Source
    Wiki study page →
  10. PubMed

    Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial

    Wadden TA, Bailey TS, Billings LK, et al. JAMA. 2021

    Source
    Wiki study page →
  11. PubMed

    Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension

    Wilding JPH, Batterham RL, Calanna S, et al. Diabetes Obes Metab. 2022

    Source
    Wiki study page →
  12. PubMed

    Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN 6)

    Marso SP, Bain SC, Consoli A, et al. N Engl J Med. 2016

    Source
    Wiki study page →
  13. PubMed

    Stable gastric pentadecapeptide BPC 157: Novel therapy in gastrointestinal tract

    Sikiric P, Seiwerth S, Rucman R, et al. Curr Pharm Des. 2018

    Source
    Wiki study page →
  14. PubMed

    Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts

    Chang CH, Tsai WC, Lin MS, et al. Molecules. 2019

    Source
    Wiki study page →
  15. PubMed

    BPC 157 and its role in accelerating wound healing

    Vukojevic J, Siroglavic M, Kasnik K, et al. Int J Mol Sci. 2022

    Source
    Wiki study page →
  16. ClinicalTrials.gov

    BPC-157 studies on ClinicalTrials.gov

    ClinicalTrials.gov. Clinical trial registry. 2024

    Source
    Wiki study page →
  17. PubMed

    BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing

    Seiwerth S, Rucman R, Turkovic B, et al. Current pharmaceutical design. 2018

    Source
    Wiki study page →
  18. PubMed

    Pentadecapeptide BPC 157 and its effects on a NSAID toxicity model: diclofenac-induced gastrointestinal, liver, and encephalopathy lesions

    Ilic S, Drmic D, Franjic S, et al. Life sciences. 2011

    Source
    Wiki study page →
  19. PubMed

    Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain

    Lee E, Padgett B. Altern Ther Health Med. 2021

    Source
    Wiki study page →
  20. PubMed

    From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management

    Yuan C, Demers A, Silva-Ortiz V, et al. Int J Mol Sci. 2026

    Source
    Wiki study page →
  21. PubMed

    Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians

    Mayfield CK, Bolia IK, Feingold CL, et al. Am J Sports Med. 2026

    Source
    Wiki study page →
  22. PubMed

    Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions

    Rahman OF, Lee SJ, Seeds WA. JAAOS Glob Res Rev. 2026

    Source
    Wiki study page →